Literature DB >> 33255624

Hydrocarbon-Stapled Peptide Based-Nanoparticles for siRNA Delivery.

Matthieu Simon1, Nabila Laroui1, Marianne Heyraud1, Guillaume Laconde1, Lamiaa M A Ali1,2, Kevin Bourbiaux1, Gilles Subra1, Lubomir L Vezenkov1, Baptiste Legrand1, Muriel Amblard1, Nadir Bettache1.   

Abstract

Small interfering Rn class="Chemical">NAs (siRn class="Chemical">NAs) are promising molecules for developing new therapies based on gene silencing; however, their delivery into cells remains an issue. In this study, we took advantage of stapled peptide technology that has emerged as a valuable strategy to render natural peptides more structured, resistant to protease degradation and more bioavailable, to develop short carriers for siRNA delivery. From the pool of stapled peptides that we have designed and synthesized, we identified non-toxic vectors that were able to efficiently encapsulate siRNA, transport them into the cell and induce gene silencing. Remarkably, the most efficient stapled peptide (JMV6582), is composed of only eight amino-acids and contains only two cationic charges.

Entities:  

Keywords:  CPP; Stapled peptides; gene silencing; siRNA

Year:  2020        PMID: 33255624      PMCID: PMC7760004          DOI: 10.3390/nano10122334

Source DB:  PubMed          Journal:  Nanomaterials (Basel)        ISSN: 2079-4991            Impact factor:   5.076


  30 in total

1.  Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells.

Authors:  Jinseu Park; Jiyoon Ryu; Kyeong-Ae Kim; Hak Joo Lee; Jae Hoon Bahn; Kyuhyung Han; Eui Yul Choi; Kil Soo Lee; Hyeok Yil Kwon; Soo Young Choi
Journal:  J Gen Virol       Date:  2002-05       Impact factor: 3.891

2.  A stapled BID BH3 helix directly binds and activates BAX.

Authors:  Loren D Walensky; Kenneth Pitter; Joel Morash; Kyoung Joon Oh; Scott Barbuto; Jill Fisher; Eric Smith; Gregory L Verdine; Stanley J Korsmeyer
Journal:  Mol Cell       Date:  2006-10-20       Impact factor: 17.970

3.  Development of helix-stabilized cell-penetrating peptides containing cationic α,α-disubstituted amino acids as helical promoters.

Authors:  Hiroko Yamashita; Takashi Misawa; Makoto Oba; Masakazu Tanaka; Mikihiko Naito; Masaaki Kurihara; Yosuke Demizu
Journal:  Bioorg Med Chem       Date:  2017-02-01       Impact factor: 3.641

Review 4.  Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer.

Authors:  Tamkin Ahmadzada; Glen Reid; David R McKenzie
Journal:  Biophys Rev       Date:  2018-01-11

5.  Synthesis and biophysical characterization of stabilized alpha-helices of BCL-2 domains.

Authors:  Gregory H Bird; Federico Bernal; Kenneth Pitter; Loren D Walensky
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

6.  A Helix-Stabilized Cell-Penetrating Peptide as an Intracellular Delivery Tool.

Authors:  Hiroko Yamashita; Makoto Oba; Takashi Misawa; Masakazu Tanaka; Takayuki Hattori; Mikihiko Naito; Masaaki Kurihara; Yosuke Demizu
Journal:  Chembiochem       Date:  2015-12-03       Impact factor: 3.164

7.  Molecular parameters of siRNA--cell penetrating peptide nanocomplexes for efficient cellular delivery.

Authors:  Alexander H van Asbeck; Andrea Beyerle; Hesta McNeill; Petra H M Bovee-Geurts; Staffan Lindberg; Wouter P R Verdurmen; Mattias Hällbrink; Ulo Langel; Olaf Heidenreich; Roland Brock
Journal:  ACS Nano       Date:  2013-04-30       Impact factor: 15.881

Review 8.  Hydrocarbon-stapled peptides: principles, practice, and progress.

Authors:  Loren D Walensky; Gregory H Bird
Journal:  J Med Chem       Date:  2014-03-06       Impact factor: 7.446

9.  Construction of histidine-containing hydrocarbon stapled cell penetrating peptides for in vitro and in vivo delivery of siRNAs.

Authors:  Soonsil Hyun; Yoonhwa Choi; Ha Neul Lee; Changki Lee; Donghoon Oh; Dong-Ki Lee; Changjin Lee; Yan Lee; Jaehoon Yu
Journal:  Chem Sci       Date:  2018-04-03       Impact factor: 9.825

10.  Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.

Authors:  Celine Bouclier; Matthieu Simon; Guillaume Laconde; Morgan Pellerano; Sebastien Diot; Sylvie Lantuejoul; Benoit Busser; Laetitia Vanwonterghem; Julien Vollaire; Véronique Josserand; Baptiste Legrand; Jean-Luc Coll; Muriel Amblard; Amandine Hurbin; May C Morris
Journal:  Theranostics       Date:  2020-01-12       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.